Skip to main content
DBV Technologies S.A. logo

DBV Technologies S.A. — Investor Relations & Filings

Ticker · DBVT ISIN · US23306J1016 US Manufacturing
Open in API
Filings indexed 553 across all filing types
Latest filing 2026-06-05 Board/Management Inform…
Country US United States of America
Listing US DBVT

About DBV Technologies S.A.

https://www.dbv-technologies.com/

DBV Technologies is a clinical-stage company focused on developing treatments for food allergies. Its core technology is the proprietary Viaskin patch, an investigational platform for epicutaneous immunotherapy (EPIT). This technology is designed to administer allergens to intact skin, aiming to re-educate the immune system and induce tolerance without significant transfer of the antigen into the bloodstream. The company's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergy. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, which has completed early-stage clinical studies.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 85% confidence The document is an SEC Form 8-K “Current Report” under Item 5.02, disclosing a compensatory arrangement—a performance share unit grant—to the company’s CEO and detailing the plan’s terms, vesting conditions, and governance. This is an announcement of a senior management appointment/compensation change rather than a full financial report or proxy statement. It falls squarely under Board/Management Information (Code: MANG).
2026-06-05 English
S-8
Regulatory Filings Classification · 92% confidence The document is a Form S-8 Registration Statement filed with the U.S. SEC under the Securities Act of 1933 to register securities pursuant to employee benefit plans. It is not an Annual Report, financial supplement, earnings release, nor a proxy or legal proceeding notice. It is a regulatory filing for compliance purposes, fitting the fallback category for miscellaneous SEC filings that do not match more specific types. Thus, it should be classified as Regulatory Filings (RNS).
2026-06-04 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a Form 8-K current report filed with the SEC on June 3, 2026, primarily disclosing the submission of matters to a vote at the company’s Annual General Meeting and providing detailed voting results for each resolution. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA). It’s not a full annual or quarterly report, audit report, proxy statement, or investor presentation, but specifically the vote results. Thus, the correct classification is DVA.
2026-06-03 English
ARS - DBV Technologies S.A. (0001613780) (Filer)
Annual Report
2026-05-11 English
DEF 14A - DBV Technologies S.A. (0001613780) (Filer)
Proxy Solicitation & Information Statement
2026-05-11 English
8-K - DBV Technologies S.A. (0001613780) (Filer)
Remuneration Information Classification · 87% confidence The document is a current report on Form 8-K describing the material terms of a performance share unit plan and related compensatory arrangements for the Company’s CEO. It does not present a full financial report or proxy solicitation but details executive compensation. This fits the "Remuneration Information (DEF 14A)" category, which covers reports detailing compensation for top executives and directors.
2026-05-05 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.